Small Molecule Inhibitors of the Neuropilin-1 Vascular Endothelial Growth Factor A (VEGF-A) Interaction
摘要:
We report the molecular design and synthesis of EG00229,2, the first small molecule ligand for the VEGF-A receptor neuropilin 1 (NRP1) and the structural characterization of NRP1-ligand complexes by NMR spectroscopy and X-ray crystallography. Mutagenesis Studies localized VEGF-A binding in the NRP1 b1 domain and it peptide Fragment of VEGF-A was shown to bind at the same site by NMR, providing the basis for small molecule design. Compound 2 demonstrated inhibition of VEGF-A binding to NRP1 and attenuated VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells was also observed. The viability of A549 lung carcinoma cells wits reduced by 2, and it increased the potency of the cytotoxic agents paclitaxel and 5-fluorouracil when given in combination. These studies provide the basis for design of specific small molecule inhibitors of ligand binding to NRP1.
DOI:
10.1021/jm901755g
作为产物:
描述:
3-氨基-2-噻吩甲酸甲酯 、 2,4-二氟苯磺酰氯 、 吡啶 以
二氯甲烷 为溶剂,
以This afforded the title compound (538 mg)的产率得到methyl 3-(2,4-difluorophenylsulfonamido)thiophene-2-carboxylate
参考文献:
名称:
Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor
[EN] THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR<br/>[FR] MODULATEURS DE RÉCEPTEUR CCR9 ET LEURS PROCÉDÉS D'UTILISATION
申请人:ENCYSIVE PHARMACEUTICALS INC
公开号:WO2009044311A1
公开(公告)日:2009-04-09
Provided are compounds of Formula (I) or of Formula (II) that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or amelioratin diseases associated with modulation of CCR9 receptor activity.